Latest News and Press Releases

James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq:...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure...

October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung...

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers,...

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete responses 32% (6/19) confirmed response rate in...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2...